OBJECTIVES: We report single center experience on the outcome and @entity137 of SBRT alone or in combination with surgery for inoperable primary and metastatic @entity96 between 2007 and 2014. @entity1 AND METHODS: @entity1 with 1-4 hepatic lesions and @entity5 diameter  <=9  cm received SBRT at 46.8Gy      3.7 in 4-6 fractions. The primary end point was local control with at least 6 months of radiographic followup, and secondary end points were @entity137 and survival. RESULTS: Eighty-seven assessable @entity1 (114 lesions) completed liver SBRT for @entity157 (39) or isolated @entity3 (48) with a median followup of 20.3 months (range 1.9-64.1). Fourteen @entity1 underwent liver transplant with SBRT as a bridging treatment or for @entity5 downsizing. Eight @entity1 completed hepatic resections in combination with planned SBRT for unresectable @entity5 . Two-year local control was 96% for @entity157 and 93.8% for @entity3 ; it was 100% for lesions  <=4  cm. Two-year overall survival was 82.3% ( @entity157 ) and 64.3% ( @entity3 ). No incidence of grade >2 treatment @entity137 was observed. CONCLUSION: In this retrospective analysis we demonstrate that liver SBRT alone or in combination with surgery is safe and effective for the treatment of isolated inoperable @entity99 and provides excellent local control rates.

Stereotactic body radiotherapy (SBRT) with or without surgery for primary and metastatic XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity96 :: ('MESH:D008113', 'Disease') :: ['liver tumors'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases'] @entity157 :: ('MESH:D006528', 'Disease') :: ['hepatoma'] @entity99 :: ('MESH:D056486', 'Disease') :: ['hepatic malignancies']
@entity96 :: (MESH:D008113,Disease) :: ['liver tumors']
